Study Suggests Some GLP-1 Users May Maintain Weight Loss With Fewer Injections
NewBeauty Facebook Pinterest Instagram Youtube find a doctor Face Adult Acne Antioxidants Anti-Aging Celebrity Chronic Skin Conditions Eye Hydration Hyperpigmentation Makeup View All Eyebrows Eye Color Foundation Fragrance Lip Color Makeovers Male Skin Care Peels Pre-Event Prep Retinoids Sensitive Skin Skin Care Skin Health Smile Sun Care Treatments Fillers Microneedling Post-Procedure Skin Care Neurotoxins Regenerative Aesthetics Skin Lifting Body Body Sculpting Breasts Butts Cellulite Hair Removal Hands + Nails Legs Pregnancy Find a Doctor Hair Bond Repair Celebrity Dry Hair Frizzy Hair Gray Hair Hair Color Hair Growth Hair Repair Scalp Health Styling + Tips Awards NB100 Awards 15th Annual Beauty Awards 2025 NewBeauty Readers’ Choice Awards Shopping Gift Guides Product Reviews NewBeauty Storefront Wellness Fitness GLP-1s Health Menopause About Us TESTTUBE Search for: Search HomeWellnessGLP-1s Study Suggests Some GLP-1 Users May Maintain Weight Loss With Fewer Injections Inside the early research on maintenance dosing. Tatiana Bido Published: Mar 10, 2026 Photo by Olga Solodilova on Unsplash A small new study suggests some patients taking GLP-1 medications may be able to maintain their weight loss even when they take the drugs less frequently. First reported by Gizmodo, the research comes from physicians at Scripps Health who examined patients who shifted to a reduced dosing schedule after reaching a weight-loss plateau. The findings, published in the journal Obesity, explore a question many patients ask once they reach their goal weight: Do weekly injections need to continue indefinitely? Researchers followed 30 patients who had already achieved significant weight loss on GLP-1 medications. Twenty-one were taking tirzepatide (Mounjaro or Zepbound) and nine were using semaglutide (Ozempic or Wegovy). Instead of continuing weekly injections, most patients spaced out their doses to roughly every two weeks, while a few extended the interval even further. The average follow-up period was about 36 weeks. During standard weekly…